Data monitoring committees: Promoting best practices to address emerging challenges

Clinical Trials

Volumn 14, Issue 2, 2017, Pages 115-123

  Fleming, Thomas R ^a   Demets, David L ^b   Roe, Matthew T ^c   Wittes, Janet ^d   Calis, Karim A ^e,f   Vora, Amit N ^c   Meisel, Alan ^g   Bain, Raymond P ^h   Konstam, Marvin A ⁱ   Pencina, Michael J ^c   Gordon, David J ^j   Mahaffey, Kenneth W ^k   Hennekens, Charles H ^l   Neaton, James D ^m   Pearson, Gail D ^j   Andersson, Tomas L G ⁿ   Pfeffer, Marc A ^o   Ellenberg, Susan S ^p  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d University of Iowa   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h MERCK RESEARCH LABORATORIES   (United States)

ⁱ TUFTS MEDICAL CENTER   (United States)

^j NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l FLORIDA ATLANTIC UNIVERSITY   (United States)

^m UNIVERSITY OF MINNESOTA   (United States)

ⁿ ASTRAZENECA R AND D   (Sweden)

^o BRIGHAM AND WOMEN S HOSPITAL   (United States)

^p UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

apprenticeship; charter; confidentiality; experience; indemnification; Independence; operating principles; regulatory; training

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; AUTHORITY; CLINICAL RESEARCH; CONTRACT; DATA ANALYSIS; EXPERIENCE; HUMAN; IN SERVICE TRAINING; INDEPENDENCE; LEADERSHIP; LEGAL LIABILITY; PRACTICE GUIDELINE; PROFESSIONAL KNOWLEDGE; PROFESSIONAL PRACTICE; PROFESSIONAL SECRECY; PROFESSIONAL STANDARD; RESPONSIBILITY; CONFIDENTIALITY; INSURANCE;

CLINICAL TRIALS DATA MONITORING COMMITTEES; CONFIDENTIALITY; HUMANS; INSURANCE; PRACTICE GUIDELINES AS TOPIC;

EID: 85017110535     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774516688915     Document Type: Article

References (44)

1. Organization, review, and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Contemp Clin Trials 1988; 9: 137-148.
2. Practical aspects of decision making in clinical trials: the Coronary Drug Project as a case study. Control Clin Trials 1981; 1: 363-376.
3. US Food and Drug Administration. The establishment and operation of clinical trial data monitoring committees for clinical trial sponsors., http://www.fda.gov/RegulatoryInformation/Guidances/ucm127069.htm (2016,. accessed 8 February 2016).
4. DeMets D, Califf R, Dixon D, et al. Issues in regulatory guidelines for data monitoring committees. Clin Trials 2004; 1: 162-169.
5. Ellenberg SS, Fleming TR, DeMets DL., Data monitoring committees in clinical trials: a practical perspective. New York: John Wiley & Sons, 2003.
6. Herson J., Data and safety monitoring committees in clinical trials. Boca Raton, FL: CRC Press, 2009.
7. Fisher MR, Roecker EB, DeMets DL., The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Inf J 2001; 35: 115-129.
8. DeMets DL, Furberg C, Friedman LM., Data monitoring in clinical trials: a case studies approach. New York: Springer, 2006.
9. Wittes J, Barrett-Connor E, Braunwald E, et al. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. Clin Trials 2007; 4: 218-234.
10. Cairns JA, Wittes J, Wyse DG, et al. Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. Am Heart J 2008; 155: 33-41.
11. Pocock S, Wilhelmsen L, Dickstein K, et al. The data monitoring experience in the MOXCON trial. Eur Heart J 2004; 25: 1974-1978.
12. DeMets D, Neaton J,. Online video for training DMC members. UW Institute for Clinical and Translational Research Web site, https://redcap.ictr.wisc.edu/surveys/?s=rke49fSLfu (2016,. accessed 9 February 2017).
13. Friedman L, Furberg C, DeMets D, et al. Fundamentals of clinical trials. 5th ed. New York: Springer, 2015.
14. Inrig JK, Califf RM, Tasneem A, et al. The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. Am J Kidney Dis 2014; 63: 771-780.
15. Sydes MR, Altman DG, Babiker AB, et al. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials 2004; 1: 48-59.
16. Califf RM, Zarin DA, Kramer JM, et al. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012; 307: 1838-1847.
17. CTTIData Monitoring Committees Project Expert Meeting: 28-29 2015, https://www.ctti-clinicaltrials.org/briefing-room/meetings/ctti-data-monitoring-committees-project-expert-meeting (. accessed 8 February 2016).
18. Califf RM, Morse MA, Wittes J, et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24: 256-271.
19. Hess CN, Roe MT, Gibson CM, et al. Independent data monitoring committees: preparing a path for the future. Am Heart J 2014; 168: 135-141.
20. Dixon DO, Freedman RS, Herson J, et al. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. Clin Trials 2006; 3: 314-319.
21. Fleming TR, Hennekens CH, Pfeffer MA, et al. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials. J Biopharm Stat 2014; 24: 968-975.
22. Clinical & Translational Science Awards. About the CTSA Consortium, https://ctsacentral.org/about-us/ctsa/ (. accessed 8 February 2016).
23. Bierer BE, Li R, Seltzer J, et al. Responsibilities of data monitoring committees: consensus recommendations. Ther Innov Regul Sci. Epub ahead of print 13 May 2016. DOI: 10.1177/2168479016646812.
24. Fleming TR., Addressing missing data in clinical trials. Ann Intern Med 2011; 54: 113-117.
25. Tereskerz PM., Data and safety monitoring boards: legal and ethical considerations for research accountability. Account Res 2010; 17: 30-50.
26. DeMets DL, Fleming TR, Rockhold F, et al. Liability issues for data monitoring committee members. Clin Trials 2004; 1: 525-531.
27. Fleming TR., Protecting the confidentiality of interim data: addressing current challenges. Clin Trials 2015; 12: 5-11.
28. Fleming TR, Sharples K, McCall J, et al. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials 2008; 5: 157-167.
29. Wittes J, Schactman M., On independent data monitoring committees in oncology clinical trials. Chin Clin Oncol 2014; 3: 40.
30. Anand SS, Wittes J, Yusuf S., What information should a sponsor of a randomized trial receive during its conduct? Clin Trials 2011; 8: 716-719.
31. Nissen SE, Wolski KE, Prcela L, et al. Effect of Naltrexone-Bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 2016; 315: 990-1004.
32. Office of Inspector General. Data and safety monitoring boards in NIH clinical trials: meeting guidance, but facing some issues., http://oig.hhs.gov/oei/reports/oei-12-11-00070.asp (. 2013, accessed 8 February 2016).
33. Yusuf S, Whitley DR, Ascenzo R, et al. Panel discussion: the operation of data monitoring committees. Stat Med 1993; 12: 527-542.
34. Meinert CL., Masked monitoring in clinical trials-blind stupidity? N Engl J Med 1998; 338: 1381-1382.
35. Friedman LM, Bristow JD, Hallstrom A, et al. Data monitoring in the Cardiac Arrhythmia Suppression Trial. Online J Curr Clin Trials 1993; 79.
36. DeMets DL, Ellenberg S, Fleming TR, et al. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. Control Clin Trials 1995; 16: 408-412.
37. Chow SC, Corey R, Lin M., On the independence of data monitoring committee in adaptive design clinical trials. J Biopharm Stat 2012; 22: 853-867.
38. DeMets DL, Fleming TR., The independent statistician for data monitoring committees. Stat Med 2004; 23: 1513-1517.
39. University of Wisconsin-Madison Statistical Data Analysis Center. Sample closed session DMC Report, 15 2014, https://www.biostat.wisc.edu/sites/default/files/sample-report-closed-2.pdf (. accessed 8 February 2016).
40. Ellenberg SS., Protecting clinical trial integrity and protecting data integrity: are we meeting the challenges? PLoS Med 2012; 9: e1001234.
41. Drazen JM, Wood AJ., Don't mess with the DSMB. N Engl J Med 2010; 363: 477-478.
42. European Medicines Agency. Committee for medicinal products for human use. Guideline on Data Monitoring Committees, 2005 http://osp.od.nih.gov/sites/default/files/resources/WC500003635.pdf (. 2005, accessed 16 June 2016).
43. Pharmaceuticals and Medical Devices Agency. Guideline on Data Monitoring Committees (PFSB/ELD notification No. 0404-1) issued in Japanese on 4 2013, https://www.pmda.go.jp/files/000204620.pdf (. accessed 16 June 2016).
44. Kereiakes DJ, Yeh RW, Driscoll-Shempp P, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.